عربي
English
Quick links
Related sites
Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Login area | Sign up
Forgot your password? Click here
Let us help you
Read about the latest topics.
Download the new version of the MOPH app 
for the latest updates on Coronavirus
 
Be Responsible
#Raise your voice
Send us any Fraudulent Action or Enquiry so we can ALL contribute to make a Difference

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

 
The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:
 
In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,
 
Health Minister Ghassan Hasbani took the following actions:
 
  1. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
  2. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
  3. The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
  4. The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.
 
These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:
 
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.
    1
    ...
    6
    7
    8
    9
    10
    11
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
All
ATC Name B/G Ingredients Dosage Form Price
B05BA02 LIPIDEM G Triglycerides, Medium Chain - 100g/500ml, Soya bean oil - 80g/500ml, Omega-3 acid triglicerides - 20g/500ml Injectable emulsion 2,486,109 L.L
J01GB06 LIKACIN G Amikacin (sulfate) - 500mg/2ml 500mg/2ml Injectable concentrated solution 349,399 L.L
D11AX18 LABDIC RELIEF G Diclofenac sodium - 1%w/w, Methyl salicylate - 8%w/w, Menthol - 2%w/w Gel 263,393 L.L
M02AA15 LOCAGEL G Diclofenac sodium (diethylamine) - 10mg/g 10mg/g Gel 223,078 L.L
D07AB02 LOCOID CRELO 0.1% B Hydrocortisone butyrate - 1mg/g 0.1% Emulsion 177,387 L.L
D07AB02 LOCOID CRELO 0.1% B Hydrocortisone butyrate - 1mg/g 0.1% Emulsion 177,387 L.L
C01AA05 LANOXIN PG B Digoxin - 0.05mg/ml 0.05mg/ml Elixir 307,740 L.L
J07CA LANTIGEN B B Streptococcus pneumoniae type 3 (antigenic extracts) - 63.2A.U./ml, Streptococcus pyogenes group A (antigenic extracts) - 126.2A.U./ml, Branhamella catarrhalis (antigenic extracts) - 39.9A.U./ml, Staphylococcus aureus (antigenic extracts) - 79.6A.U./ml, Haemophilus influenzae type b (antigenic extracts) - 50.2A.U./ml, Klebsiella pneumoniae (antigenic extracts) - 39.8A.U./ml Drops suspension 916,501 L.L
S01BA14 LOTEMAX B Loteprednol etabonate - 0.5% 0.5% Drops suspension 1,038,790 L.L
S01CA02 LOXTRA G Prednisolone acetate - 2mg/ml, Tetrahydrozoline HCl - 0.4mg/ml, Ofloxacin - 3mg/ml Drops suspension 423,310 L.L
S01XA20 LUBRI-TEARS G Carmellose sodium - 2mg Drops solution 792,867 L.L
S01CA01 LEVIOSA G Levofloxacin - 5mg/ml, Dexamethasone - 1mg/ml Drops solution 1,427,161 L.L
S01EA05 LUMIFY B Brimonidine tartrate - 0.025% Drops solution 1,888,099 L.L
S01EE03 LUMIGAN B Bimatoprost - 0.1mg/ml 0.1mg/ml Drops solution 740,457 L.L
S01EE03 LUMIGAN B Bimatoprost - 0.1mg/ml 0.1mg/ml Drops solution 740,457 L.L
S01ED51 LOPROSTAN G Timolol - 5mg/ml, Latanoprost - 50?g/ml Drops 768,678 L.L
D07XC01 LOTRIDERM B Betamethasone (dipropionate) - 0.5mg/g, Clotrimazole - 10mg/g Cream 470,345 L.L
D01AC12 LOMEXIN B Fenticonazole nitrate - 2g/100g 2% Cream 758,029 L.L
D01AE15 LAMISIL B Terbinafine HCl - 10mg/g 1% Cream 616,824 L.L
D01AE15 LAMIFEN G Terbinafine HCl - 1% 1% Cream 350,743 L.L
D01AE15 LAMINOX G Terbinafine HCl - 10mg/g 10mg/g Cream 453,067 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 1mg/g 0.1% Cream 215,015 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 1mg/g 0.1% Cream 215,015 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 25mg 25mg Capsule, hard 87,161,381 L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard 15,343,847 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard L.L
L04AA27 LYXIA G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule, hard 32,406,715 L.L
L04AA27 LYXIA G Fingolimod Hydrochloride - 0.25mg 0.5mg Capsule, hard 32,406,715 L.L
    1
    ...
    6
    7
    8
    9
    10
    11
Sitemap
© Copyrights reserved to Ministry of Public Health 2025